

Lupron Depot is hard to find due to ongoing shortages, limited manufacturers, and high demand. Learn why and what you can do to get your injection on time.
You show up for your scheduled Lupron Depot injection and your doctor's office tells you they can't get it. Or your specialty pharmacy says it's backordered. If this sounds familiar, you're one of thousands of patients dealing with this frustrating reality in 2026.
Lupron (Leuprolide Acetate) is a critical medication for people with advanced prostate cancer, endometriosis, uterine fibroids, and central precocious puberty in children. Missing a dose isn't just inconvenient — it can mean a return of painful symptoms or a setback in cancer treatment.
So why is Lupron so hard to find? Let's break it down.
Lupron Depot is a GnRH (gonadotropin-releasing hormone) agonist made by AbbVie. It works by shutting down the body's production of sex hormones like testosterone and estrogen. Doctors prescribe it as an intramuscular injection given every 1, 3, 4, or 6 months depending on the condition and dose strength.
It comes in several formulations:
Because Lupron treats such a wide range of serious conditions, demand is consistently high. And when supply can't keep up, patients feel it.
Lupron Depot has experienced recurring shortages since 2020. The American Society of Health-System Pharmacists (ASHP) tracked active shortages of Leuprolide Acetate long-acting suspension from July 2020 through May 2022. While supply has partially stabilized, certain strengths continue to face intermittent availability problems in 2026.
Lupron Depot is a complex injectable product — it's a specialized depot suspension that requires precise manufacturing conditions. Any disruption at the manufacturing facility can ripple through the supply chain for months.
AbbVie is the sole manufacturer of Lupron Depot. There is no true generic equivalent for the depot formulation. While other Leuprolide products exist (like Eligard, which is a subcutaneous depot), they aren't interchangeable with Lupron Depot without a new prescription. This single-source dependency means if AbbVie has a production issue, there's no backup.
Unlike medications you pick up at your local pharmacy, Lupron Depot is typically a "buy-and-bill" medication — meaning your doctor's office purchases it from a specialty distributor and administers it to you directly. This adds another layer of complexity. When distributors run low, individual practices may not be able to order the strength they need, even if supply exists elsewhere in the country.
Lupron is prescribed across multiple specialties — urology, oncology, gynecology, pediatric endocrinology, and reproductive medicine. As the population ages and prostate cancer diagnoses remain common, demand for Lupron continues to grow. Expanded off-label uses, including gender-affirming care, have also increased the patient population relying on this drug.
If your provider tells you Lupron is unavailable, don't panic. Here are steps you can take:
For more tips, read our guide on how to find Lupron in stock near you.
Lupron Depot is a critical medication, and the difficulty in finding it is a real problem for patients across the country. The combination of a single manufacturer, complex production process, recurring shortages, and high demand makes it one of the harder specialty drugs to reliably access.
The good news is that tools like Medfinder exist specifically to help patients and providers navigate these challenges. If you're struggling to find Lupron, you're not stuck — there are resources and alternatives available.
Stay informed by reading our Lupron shortage update for 2026.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.